A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Not Recruiting

Trial ID: NCT02335918


This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects.

Official Title

A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

A. Dimitrios Colevas, MD
A. Dimitrios Colevas, MD

Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)


Key Inclusion Criteria:

   1. Histologically-diagnosed advanced (unresectable and/or metastatic) Non-small Cell Lung
   Cancer (Phase l only), Melanoma (Phase l only), Colorectal, Head and Neck SCC
   (squamous cell carcinoma), Ovarian Cancer, Glioblastoma or Renal Cell Carcinoma.

      - 1a. Head and Neck

   Stage III/IV squamous cell carcinoma; Tumor progression or recurrence within 6 months
   of last dose of platinum therapy in the adjuvant, primary, recurrent or metastatic
   setting (or within 9 months if the patient received > 1 platinum-based chemotherapy
   regimen in the metastatic setting). Active brain metastases or leptomeningeal
   metastases are excluded; nasopharyngeal cancer, confirmed recurrent or metastatic
   carcinoma of the nasopharynx and salivary gland or non-squamous histologies are also

      - 1b. Ovarian

   Recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal
   carcinoma requiring original or subsequent relapse histologic documentation. A
   platinum-taxane based chemotherapy regimen as frontline therapy must have been

   Any histologic diagnosis of borderline, low malignant potential epithelial carcinoma
   are excluded.

      - 1c. Colorectal Cancer -Enrollment Completed

   Metastatic or recurrent; prior treatment progression during, after, or intolerant
   following the last administration of approved standard therapies (required therapies

      - 1d. Glioblastoma -Enrollment Completed

   Have histologically confirmed World Health Organization Grade IV malignant glioma

      - Previous first line therapy with at least radiotherapy and temozolomide.

      - Participants must have shown unequivocal evidence of tumor progression.

      - More than one relapse, secondary glioblastoma and prior treatment with
      bevacizumab are excluded.

   An interval of at least 12 weeks from the completion of radiation therapy to start of
   study treatment is required.

      - 1e. Renal Cell Carcinoma

   Have histologically confirmed diagnosis of predominant clear cell renal cell

      - Must have received 1 or 2 prior anti-angiogenic therapies.

      - No more than 5 total previous regimens of systemic therapy, including cytokines
      and cytotoxic chemotherapy.

      - Disease progression during or after the last treatment regimen and within 6
      months before study entry.

   2. No more than 5 prior anticancer regimens for advanced (recurrent, locally advanced or
   metastatic) disease except for patients with GBM which must have first recurrence of
   GBM by diagnostic biopsy or contrast enhanced magnetic resonance imaging (MRI).

   3. Measurable (target) disease.

   4. Life expectancy ≥ 12 weeks.

   5. If of childbearing potential (male or female), agree to practice an effective form of
   contraception during study treatment and for at least 23 weeks after for female and 31
   weeks after for male following last treatment dose.

Key Exclusion Criteria:

   1. History of severe hypersensitivity reactions to other monoclonal antibodies.

   2. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody.

   3. Receipt of anti-CTLA-4 or anti-CD27 antibody within 3 months prior to the planned
   start of study treatment.

   4. Use of any monoclonal based therapies within 2-4 weeks prior to the first dose of
   study treatment.

   5. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to
   the planned start of study treatment.

   6. BRAF/MEK inhibitors within 2 weeks prior to the first dose of study treatment.

   7. Systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or
   radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose of
   study treatment.

   8. Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within
   2 weeks prior to first dose of study treatment.

   9. Other prior malignancy, except for adequately treated basal or squamous cell skin
   cancer or in situ cancers; or any other cancer from which the patient has been
   disease-free for at least 3 years.

10. Active, untreated central nervous system metastases.

11. Active autoimmune disease or a documented history of autoimmune disease

12. Active diverticulitis.

13. Interstitial lung disease that is symptomatic or may interfere with the detection or
   management of suspected drug-related pulmonary toxicity.

14. Significant cardiovascular disease


drug: Combination of varlilumab and nivolumab

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.